Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Saved in:
Bibliographic Details
Title: Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Authors: Stuart ASV; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Shaw RH; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Liu X; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Greenland M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Andrews NJ; Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK; Immunisation and Countermeasures Division, National Infection Service, UK Health Security Agency, London, UK., Cameron JC; Public Health Scotland, Glasgow, Scotland, UK., Charlton S; UK Health Security Agency, Porton Down, Salisbury, UK., Clutterbuck EA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Collins AM; Liverpool School of Tropical Medicine, Liverpool, UK., Darton T; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Dinesh T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Duncan CJA; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle, UK., England A; UK Health Security Agency, Porton Down, Salisbury, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Ferreira DM; Liverpool School of Tropical Medicine, Liverpool, UK., Finn A; School of Population Health Sciences, and School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Goodman AL; Department of Infection, and NIHR BRC, Guy's and St Thomas' NHS Foundation Trust, London, UK; MRC Clinical Trials Unit, University College London, London, UK., Green CA; NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK., Hallis B; UK Health Security Agency, Porton Down, Salisbury, UK., Heath PT; The Vaccine Institute, St George's University of London, London, UK., Hill H; Liverpool School of Tropical Medicine, Liverpool, UK., Horsington BM; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Lambe T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Chinese Academy of Medical, Science Oxford Institute, University of Oxford, Oxford, UK., Lazarus R; North Bristol NHS Trust, Bristol, UK., Libri V; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK., Lillie PJ; Infection Research Group, Hull University Teaching Hospitals NHS Trust, Hull, UK., Mujadidi YF; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Payne R; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Plested EL; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Provstgaard-Morys S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Ramasamy MN; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Ramsay M; Immunisation and Countermeasures Division, National Infection Service, UK Health Security Agency, London, UK., Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Screaton GR; Chinese Academy of Medical, Science Oxford Institute, University of Oxford, Oxford, UK; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Singh N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Turner DPJ; University of Nottingham, Nottingham, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK., Turner PJ; National Heart and Lung Institute, Imperial College London, London, UK., Vichos I; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., White R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Nguyen-Van-Tam JS; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK., Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford NIHR-Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: matthew.snape@paediatrics.ox.ac.uk.
Corporate Authors: Com-COV2 Study Group
Source: Lancet (London, England) [Lancet] 2022 Jan 01; Vol. 399 (10319), pp. 36-49. Date of Electronic Publication: 2021 Dec 06.
Publication Type: Clinical Trial, Phase II; Equivalence Trial; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(21)02718-5